ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.
作者信息
Kang Min Kyung
机构信息
Division of Cardiology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, Korea.
出版信息
J Cardiovasc Imaging. 2020 Oct;28(4):254-256. doi: 10.4250/jcvi.2020.0099.
Abstract
摘要
相似文献
1
ECG Monitoring of Reactions to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.射血分数降低的心力衰竭患者中沙库巴曲缬沙坦反应的心电图监测
J Cardiovasc Imaging. 2020 Oct;28(4):254-256. doi: 10.4250/jcvi.2020.0099.
2
Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭：聚焦对生活质量的影响——一项随机临床试验的系统评价和荟萃分析
Cureus. 2023 Nov 11;15(11):e48674. doi: 10.7759/cureus.48674. eCollection 2023 Nov.
3
Prior Authorization, Copayments, and Utilization of Sacubitril/Valsartan in Medicare and Commercial Plans in Patients With Heart Failure With Reduced Ejection Fraction.心力衰竭伴射血分数降低患者在医疗保险和商业计划中使用沙库巴曲缬沙坦的预先授权、共同支付和利用情况。
Circ Cardiovasc Qual Outcomes. 2021 Sep;14(9):e007665. doi: 10.1161/CIRCOUTCOMES.120.007665. Epub 2021 Sep 1.
4
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction.评估沙库巴曲缬沙坦钠作为射血分数降低和射血分数保留的心力衰竭的治疗选择。
Expert Opin Pharmacother. 2022 Feb;23(3):303-320. doi: 10.1080/14656566.2022.2027909. Epub 2022 Jan 20.
5
Sacubitril/Valsartan Improves Left Ventricular Ejection Fraction and Reverses Cardiac Remodeling in Taiwanese Patients with Heart Failure and Reduced Ejection Fraction.沙库巴曲缬沙坦可改善台湾射血分数降低的心力衰竭患者的左心室射血分数并逆转心脏重塑。
Acta Cardiol Sin. 2020 Mar;36(2):125-132. doi: 10.6515/ACS.202003_36(2).20190812A.
6
Heart Failure Population with Therapeutic Response to Sacubitril/Valsartan, Spironolactone and Candesartan: FDA Perspective.对沙库巴曲缬沙坦、螺内酯和坎地沙坦有治疗反应的心力衰竭人群：美国食品药品监督管理局的观点
Ther Innov Regul Sci. 2022 Jan;56(1):4-7. doi: 10.1007/s43441-021-00347-z. Epub 2021 Oct 26.
7
Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.血管紧张素-脑啡肽酶抑制剂在射血分数保留的心力衰竭中的应用。
N Engl J Med. 2019 Oct 24;381(17):1609-1620. doi: 10.1056/NEJMoa1908655. Epub 2019 Sep 1.
8
Impact of Sacubitril/Valsartan on Lipid Parameters in Patients with Heart Failure with Reduced Ejection Fraction.沙库巴曲缬沙坦对射血分数降低的心力衰竭患者血脂参数的影响。
Clin Drug Investig. 2022 Jun;42(6):533-540. doi: 10.1007/s40261-022-01161-7. Epub 2022 May 30.
9
The Effect of Sacubitril/Valsartan on Left Ventricular Myocardial Deformation in Heart Failure with Preserved Ejection Fraction (PARAMOUNT trial).沙库巴曲缬沙坦对射血分数保留心力衰竭患者左心室心肌变形的影响（PARAMOUNT 试验）。
J Card Fail. 2023 Jun;29(6):968-973. doi: 10.1016/j.cardfail.2023.03.019. Epub 2023 Apr 7.
10
Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.射血分数保留的心力衰竭患者的心房颤动：PARAGON-HF试验
JACC Heart Fail. 2022 May;10(5):336-346. doi: 10.1016/j.jchf.2022.01.018. Epub 2022 Apr 6.
本文引用的文献
1
Changes in QRS Duration Are Associated with a Therapeutic Response to Sacubitril-valsartan in Heart Failure with Reduced Ejection Fraction.QRS波时限变化与沙库巴曲缬沙坦对射血分数降低的心力衰竭治疗反应相关。
J Cardiovasc Imaging. 2020 Oct;28(4):244-253. doi: 10.4250/jcvi.2020.0025.
2
Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease.沙库巴曲缬沙坦治疗射血分数降低的心力衰竭合并终末期肾病患者。
ESC Heart Fail. 2020 Jun;7(3):1125-1129. doi: 10.1002/ehf2.12659. Epub 2020 Mar 10.
3
Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.沙库巴曲缬沙坦：一种新型血管紧张素受体脑啡肽酶抑制剂。
Indian Heart J. 2018 Jul;70 Suppl 1(Suppl 1):S102-S110. doi: 10.1016/j.ihj.2018.01.002. Epub 2018 Jan 8.
4
2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2016年美国心脏病学会/美国心脏协会/美国心力衰竭学会关于心力衰竭新药物治疗的重点更新：2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南更新：美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2016 Sep 27;134(13):e282-93. doi: 10.1161/CIR.0000000000000435. Epub 2016 May 20.
5
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.心力衰竭中的中性肽链内切酶途径：沙库巴曲缬沙坦应用的综述与指南
Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20.
6
Valsartan/Sacubitril for Heart Failure: Reconciling Disparities Between Preclinical and Clinical Investigations.
JAMA. 2016 Jan 5;315(1):25-6. doi: 10.1001/jama.2015.17632.
7
Neprilysin Inhibition in Heart Failure with Reduced Ejection Fraction: A Clinical Review.射血分数降低的心力衰竭中中性肽链内切酶抑制作用：一项临床综述。
Pharmacotherapy. 2015 Sep;35(9):823-37. doi: 10.1002/phar.1629.
8
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.根据年龄分析LCZ696（沙库巴曲缬沙坦）的疗效和安全性：来自PARADIGM-HF研究的见解
Eur Heart J. 2015 Oct 7;36(38):2576-84. doi: 10.1093/eurheartj/ehv330. Epub 2015 Jul 31.
9
Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis.联合血管紧张素受体阻断和中性肽链内切酶抑制可减弱血管紧张素II介导的肾细胞胶原合成。
Int J Cardiol. 2015;186:104-5. doi: 10.1016/j.ijcard.2015.03.116. Epub 2015 Mar 11.
10
Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.血管紧张素受体脑啡肽酶抑制剂 LCZ696 通过减少心脏纤维化和肥大来减轻心肌梗死后的心脏重构和功能障碍。
Circ Heart Fail. 2015 Jan;8(1):71-8. doi: 10.1161/CIRCHEARTFAILURE.114.001785. Epub 2014 Oct 31.
Zotero 插件